Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Polo-like kinases (PLKs) are crucial for cell cycle regulation and cancer cell survival.
• Targeting PLKs presents a potential therapeutic strategy for various malignancies.
• Well-differentiated thyroid cancer (WDTC) remains a significant clinical challenge.

Purpose of the Study:

• To evaluate the therapeutic efficacy of volasertib, a PLK inhibitor, in WDTC.
• To investigate the synergistic effects of volasertib in combination with sorafenib.
• To assess the safety profile of volasertib-based therapies.

Main Methods:

• In vitro proliferation assays using WDTC cell lines.
• Cell cycle analysis (S and G2/M phases) and apoptosis induction (caspase-3 activity).
• In vivo studies using thyroid cancer xenograft and tumor models, including combination therapy.

Main Results:

• Volasertib demonstrated dose-dependent inhibition of WDTC cell proliferation.
• Volasertib induced cell cycle arrest at G2/M phase and promoted apoptosis.
• Combination of volasertib and sorafenib exhibited synergistic anti-cancer effects in vitro and in vivo.
• Volasertib-based treatments showed promising safety profiles in animal models.

Conclusions:

• Volasertib is a potent inhibitor of WDTC cell growth and a promising therapeutic agent.
• Combination therapy with sorafenib enhances volasertib's efficacy against WDTC.
• Volasertib warrants further investigation for clinical application in WDTC treatment.